QCLS
Q/C Technologies, Inc.
$2.58
-5.49%
2026-08-21
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Key Fundamentals
EPS (TTM)
$-8.49
ROE
-62.6%
Profit Margin
0.0%
Price/Book
1.06
Beta
2.11
Market Cap
$21.8M
Avg Volume (10D)
103K
Recent Breakout Signals
No recent breakout signals detected for QCLS.
Recent Price Range (60 Days)
60D High
$4.80
60D Low
$2.50
Avg Volume
232K
Latest Close
$2.58
Get breakout alerts for QCLS
Sign up for Breakout Scanner to receive daily notifications when QCLS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Q/C Technologies, Inc. (QCLS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors QCLS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. QCLS operates in the Technology sector within the Computer Hardware industry. Data is provided for informational purposes only and does not constitute financial advice.